Last reviewed · How we verify
Induction of labor with PGE2
Induction of labor with PGE2, marketed by Guangzhou Women and Children's Medical Center, holds a position in the labor induction market with a key composition patent expiring in 2028. The drug leverages its established market presence and the lack of immediate generic competition as its primary strength. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | Induction of labor with PGE2 |
|---|---|
| Also known as | Dinoprostone suppositories |
| Sponsor | Guangzhou Women and Children's Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PGE2 Followed by Oxytocin vs Oxytocin in Term PROM (POXY-PROM) (NA)
- Mechanical Dilation of the Cervix in a Scarred Uterus (NA)
- Early V/S Delayed Induction of Labour in Patients With Prelabour Rupture of Membranes (NA)
- Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening (PHASE3)
- Induction of Labor - Comparison Propess With Prostaglandin E2 Vaginal Gel and Balloon Catheter (PHASE4)
- Cook´s Balloon Versus Dinoprostone for Labor Induction of Term Pregnancies With Fetal Growth Restriction (PHASE3)
- Misoprostol Versus Dinoprostone in Induction of Labor (NA)
- Comparison of the Effectiveness, Safety, and Satisfaction of Different Methods for Labor Induction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: